Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to his Oral Answer of 20 March 2018, Official Report, column 156, on motor neurone disease, which projects received that £52 million investment; and which 24 clinical trials are being recruited to.
In 2016-17, the National Institute for Health Research (NIHR) invested £52.2 million into health research covered by the ‘Neurological conditions’ category of the UK Health Research Classification System. This £52.2 million was used to fund and support a range of research studies and research infrastructure for neurological conditions and within that, £4.58 million was spent specifically on Motor Neurone Disease (MND) and closely-related conditions.
The NIHR provides the support, expertise and facilities that the NHS needs to undertake world-leading research funded by the NIHR, and other public, charity and life sciences industry partners, by funding a range of infrastructure facilities.
The NIHR Clinical Research Network is currently supporting 19 non-commercial studies and clinical trials on MND and closely-related conditions which are open and recruiting participants. The non-commercial studies are listed in the table below. There are currently two commercial studies which are also recruiting participants.
In 2016-17, the NIHR Research Infrastructure supported 23 studies and trials on MND and closely-related conditions in the NIHR Biomedical Research Centres, Units and other research infrastructure. The majority of these studies have been funded by research charities including the Motor Neurone Disease Association, other research funders and the life sciences industry.
NIHR Clinical Research Network supported Non-Commercial studies on MND and closely-related conditions which are open and recruiting participants
CPMS Study ID | Study Short Name |
12497 | Trajectories of Outcome in Neurological Conditions Phase 3 Consent and questionnaire |
12495 | Trajectories of Outcome in Neurological Conditions Phase 2 Demographics and Clinical Info |
12768 | Motor System Genomics, version 1.0 |
6160 | ALS Biomarkers Study |
35238 | Tonic 2 Phase 4 |
20690 | MND Register for England, Wales and Northern Ireland |
12118 | Trajectories of Outcome in Neurological Conditions Phase 1 |
13182 | CSF collection in patients with neurodegenerative diseases |
16242 | BioMOx Phase 2: The Oxford Study for Biomarkers in Motor Neuron Disease |
31877 | A Multicentre Biomarker Study in Neurodegeneration |
20372 | Contributing clinical MRI scans to multi-centre collaboration |
19128 | Tongue EIM |
17831 | Using MRI to investigate energy metabolism in MND |
34909 | Improving support for family and friends caring for people with MND |
35042 | Serial fasciculation measurements in motor neurone disease |
17557 | Care Augmentation by Location-linked messaging CALL-Me |
32678 | MIROCALS_H2020/PHRC-N/2014/GB-01_ID-IL-2_Neuro-Inflammation in ALS Pts |
36434 | Change in MND |
37175 | ProSec 3 |